Journal of Endocrinological Investigation

, Volume 18, Issue 4, pp 277–282 | Cite as

Bone mineral metabolism and thyroid replacement therapy in congenital hypothyroid infants and young children

  • G. Weber
  • Stefano Mora
  • A. Bellini
  • M. Bosco
  • C. Prinster
  • V. Siragusa
  • B. di Natale
  • G. Chiumello


Impairment of calcium metabolism and low bone density have been found in hypothyroid adults. We investigated the effect of thyroid replacement therapy on calcium metabolism and bone mineralization in congenital hypothyroid (CH) infants and children. One hundred and 16 Caucasian CH consecutive patients were studied and were grouped according to their age: 23 patients at diagnosis, 20 at 3 mo, 24 at 6 mo, 25 at 12 mo and 24 at 36 mo. Thyroid replacement therapy was started at an initial dose of 6–8 μg/kg/day of L-thyroxine, and then decreased progressively. Calcium, phosphorus, magnesium, alkaline phosphatase (AP), parathyroid hormone (PTH) and osteocalcin (BGP) were measured as calcium metabolism indices. Bone mineral content (BMC) was measured at the mid-portion of the right radius AP, PTH and BGP concentrations were significantly higher in subjects at 3 mo of age (p<0.05). This rise coincided with the end of the period of maximum dosage of L-thyroxine. Mild asymptomatic hypercalcemia was observed in 20 patients. All the other indices did not differ between age groups. BMC values and BMC annual increment were not different from those calculated for age-matched controls. We found that L-thyroxine replacement therapy does not alter bone mineralization of CH infants and children. Only a transitory increase of osteoblastic function was observed after the first few months of therapy.


Congenital hypothyroidism bone metabolism bone mineral content children 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Mosekilde L., Eriksen E.F., Charles P. Effects of thyroid hormones on bone metabolism and mineral metabolism. Endocrinol. Metab. Clin. North Am. 19: 35, 1990.PubMedGoogle Scholar
  2. 2.
    Bouillon R., Muls E., De Moor P. Influence of thyroid function on the serum concentration of 1,25-dihydroxyvitamin D3. J. Clin. Endocrinol. Metab. 51: 793, 1980.PubMedCrossRefGoogle Scholar
  3. 3.
    Krøener B., Jørgensen J.V., Nielsen S.P. Spinal bone mineral content in myxoedema and thyrotoxicosis. Effects of thyroid hormones and antithyroid treatment. Clin. Endocrinol. (Oxf.) 18: 439, 1983.CrossRefGoogle Scholar
  4. 4.
    Melsen F., Mosekilde L. Morphometric and dynamic studies of bone changes in hyperthyroidism. Acta Pathol. Microbiol. Scand. 85: 141, 1977.Google Scholar
  5. 5.
    Eriksen E.F., Mosekilde L., Melsen F. Trabecular bone remodeling and bone balance in hyperthyroidism. Bone 6: 421, 1985.PubMedCrossRefGoogle Scholar
  6. 6.
    Auwerx J., Bouillon R. Mineral and bone metabolism in thyroid disease: a review. Q.J. Med. 232: 737, 1986.Google Scholar
  7. 7.
    Fraser S.A., Smith D.A., Anderson J.B., Wilson G.M. Osteoporosis and fractures following thyrotoxicosis. Lancet 1: 981, 1975.Google Scholar
  8. 8.
    Linde J., Friis T. Osteoporosis in hyperthyroidism estimated by photon absorptiometry. Acta Endocrinol. (Copenh.) 91: 437, 1979.Google Scholar
  9. 9.
    Toh S.H., Claunch B.C., Brown P.H. Effect of hyperthyroidism and its treatment on bone mineral content. Arch. Int. Med. 145: 883, 1985.CrossRefGoogle Scholar
  10. 10.
    Campos-Pastor M.M., Muñoz-Torres M., Escobar-Jiménez F., Ruiz de Almodovar M., Jodar Gimeno E. Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner. 21: 1, 1993.PubMedCrossRefGoogle Scholar
  11. 11.
    Jastrup B., Mosekilde L., Melsen F., Lund Bi., Lund Bj., Sørensen O.H. Serum levels of vitamin D metabolites and bone remodeling in hyperthyroidism. Metabolism 31: 126, 1982.PubMedCrossRefGoogle Scholar
  12. 12.
    Campos-Pastor M.M., Muñoz-Torres M., Escobar-Jiménez F., Ruiz de Almodovar M., Jodar Gimeno E. Bone mass in females with different thyroid disorders: influence of menopausal status. Bone Miner. 21: 1, 1993.PubMedCrossRefGoogle Scholar
  13. 13.
    Szabo Z.S., Ritzl F. Hypercalcemia in hyperthyroidism — role of age and goiter type. Klin. Wochenschr. 59: 275, 1981.PubMedCrossRefGoogle Scholar
  14. 14.
    Parfitt A.M., Dent CE. Hyperthyroidism and hypercalcemia. Q.J. Med. 154: 171,1970.Google Scholar
  15. 15.
    Macfarlane A., Mawer E.B., Berry J., Hann J. Vitamin D metabolism in hyperthyroidism. Clin. Endocrinol. (Oxf.) 17: 51, 1982.CrossRefGoogle Scholar
  16. 16.
    Garrel D.R., Delmas P.D., Malaval L., Tourniaare J. Serum bone GLA protein: a marker of bone turnover in hyperthyroidism. J. Clin. Endocrinol. Metab. 62: 1052, 1986.PubMedCrossRefGoogle Scholar
  17. 17.
    Lukert B.P., Higgins J.C., Stoskopf M.M. Serum osteocalcin is increased in patients with hyperthyroidism and decreased in patients receiving glucocorticoids. J. Clin. Endocrinol. Metab. 62: 1056, 1986.PubMedCrossRefGoogle Scholar
  18. 18.
    Martinez M.E., Herranz L., de Pedro C., Pallardo L.F. Osteocalcin levels in patients with hyper- and hypothyroidism. Horm. Metab. Res. 18: 212, 1986.PubMedCrossRefGoogle Scholar
  19. 19.
    Lee M.S., Kim S.Y., Lee M.C., Cho B.Y., Lee M.K., Koh C.-S., MinH.K. Negative correlation between the change in bone mineral density and serum osteocalcin in patients with hyperthyroidism. J. Clin. Endocrinol. Metab. 70: 766, 1990.PubMedCrossRefGoogle Scholar
  20. 20.
    Ross D.S. Subclinical hyperthyroidism: possible danger of overzealous thyroxine replacement therapy. Mayo Clin. Proc. 63: 1223, 1988.PubMedCrossRefGoogle Scholar
  21. 21.
    Ross D.S., Neer R.M., Ridgway E.C., Daniels G.H. Subclinical hyperthyroidism and reduced bone density as a possible result of prolonged suppression of the pituitary-thyroid axis with L-thyroxine. Am. J. Med. 32: 1167, 1987.CrossRefGoogle Scholar
  22. 22.
    Paul T.L., Kerrigan J., Kelly A.M., Braverman L.E., Baran D.T. Long-term L-thyroxine therapy is associated with decreased hip bone density in premenopausal women. JAMA 259: 3137, 1988.PubMedCrossRefGoogle Scholar
  23. 23.
    Ribot C., Tremolliere F., Pouilles J.M., Louvet J.P. Bone mineral density and thyroid hormone therapy. Clin. Endocrinol. (Oxf.) 33: 143, 1990.CrossRefGoogle Scholar
  24. 24.
    Toh S.H., Brown P.H. Bone mineral content in hypothyroid male patients with hormone replacement: a 3-year study. J. Bone Miner. Res. 5: 463, 1990.PubMedCrossRefGoogle Scholar
  25. 25.
    Ross D.S., Ardisson L.J., Nussbaum S.R., Meskell M.J. Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism. J. Clin. Endocrinol. Metab. 72: 507, 1991.PubMedCrossRefGoogle Scholar
  26. 26.
    Stepán J.J., ’lmanová Z. Biochemical assessment of bone loss on long-term thyroid hormone treatment. Bone Miner. 17: 377, 1992.PubMedCrossRefGoogle Scholar
  27. 27.
    Tau C., Garabedian M., Farriaux J.P., Czernichow P., Pomarede R., Balsan S. Hypercalcemia in infants with congenital hypothyroidism and its relation to vitamin D and thyroid hormones. J. Pediatr. 109: 808, 1986.PubMedCrossRefGoogle Scholar
  28. 28.
    Cameron J.R., Mazess R.B., Sorenson S.A. Precision and accuracy of bone mineral determination by direct photon absorptiometry. Invest. Radiol. 3: 11, 1968.CrossRefGoogle Scholar
  29. 29.
    Steichen J.J., Kaplan B., Edwards N., Tsang R.C. Bone mineral content in full-term infants measured by direct photon absorptiometry. Am. J. Roentgenol. 126: 1283, 1976.CrossRefGoogle Scholar
  30. 30.
    Guarneri M.P., Weber G., Bianchi C., Gallia P., Chiumello G. Bone mineral content in preterm infants at 40 weeks of gestational age. Dev. Physiopath. Clin. 2: 151, 1991.Google Scholar
  31. 31.
    Greenspan S.L., Greenspan F.S., Resnick N.M., Block J.E., Friedlander A.L., Genant H.K. Skeletal integrity in premenopausal and postmenopausal women receiving long-term L-thyroxine therapy. Am. J. Med. 91: 5, 1991.PubMedCrossRefGoogle Scholar
  32. 32.
    Franklyn J.A., Betteridge J., Daykin J., Holder R., Oates G.D., Parle J.V., Lilley J., Heath D.A., Sheppard M.C. Long-term thyroxine treatment and bone mineral density. Lancet 340: 9, 1992.PubMedCrossRefGoogle Scholar
  33. 33.
    Ross D.S., Ardisson L.J., Nussbaum S.R., Meskell M.J. Serum osteocalcin in patients taking L-thyroxine who have subclinical hyperthyroidism. J. Clin. Endocrinol. Metab. 72: 507, 1991.PubMedCrossRefGoogle Scholar
  34. 34.
    Demeester-Mirkine N., Bergmann P., Body J.J., Corvilain J. Calcitonin and bone mass status in congenital hypothyroidism. Calcif. Tissue Int. 46: 222, 1990.PubMedCrossRefGoogle Scholar
  35. 35.
    Fraser W.D., Logue F.C., MacRitchie K., Wilson R.M., Gray H.W., Beastall G.H., O’Reilly D. StJ. Intact parathyroid hormone concentration and cyclic AMP metabolism in thyroid disease. Acta Endocrinol.(Copenh.) 124: 652, 1991.Google Scholar
  36. 36.
    Harvey R.D., McHardy K.C., Reid I.W., Paterson F., Bewsher P.D., Duncan A., Robins S.P. Measurement of bone collagen degradation in hyperthyroidism and during thyroxine replacement therapy using pyridinium cross-links as specific urinary markers. J. Clin. Endocrinol. Metab. 72: 1189, 1991.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 1995

Authors and Affiliations

  • G. Weber
    • 1
  • Stefano Mora
    • 1
  • A. Bellini
    • 2
  • M. Bosco
    • 1
  • C. Prinster
    • 1
  • V. Siragusa
    • 1
  • B. di Natale
    • 1
  • G. Chiumello
    • 1
  1. 1.Clinica Pediatrica III, Istituto Scientifico H San RaffaeleUniversità degli Studi di MilanoItaly
  2. 2.Istituto di Biometria e Statistica MedicaUniversità degli Studi di MilanoMilanoItaly

Personalised recommendations